Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,763 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,763 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $20.20, for a total transaction of $55,812.60. Following the completion of the transaction, the insider owned 1,946 shares of the company’s stock, valued at $39,309.20. The trade was a 58.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL traded down $0.39 during midday trading on Friday, hitting $20.15. The stock had a trading volume of 289,270 shares, compared to its average volume of 406,556. The company’s 50-day moving average price is $23.57 and its 200-day moving average price is $31.81. The company has a market capitalization of $611.15 million, a P/E ratio of -45.80 and a beta of 1.11. The company has a quick ratio of 6.53, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). The company had revenue of $84.23 million for the quarter, compared to analyst estimates of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. As a group, equities research analysts predict that Castle Biosciences, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Castle Biosciences by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after acquiring an additional 27,511 shares during the last quarter. RTW Investments LP bought a new stake in Castle Biosciences during the 4th quarter worth approximately $82,283,000. Principal Financial Group Inc. grew its holdings in Castle Biosciences by 0.7% during the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after acquiring an additional 13,289 shares during the last quarter. Portolan Capital Management LLC grew its holdings in Castle Biosciences by 1.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock worth $34,499,000 after acquiring an additional 25,539 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Castle Biosciences by 7.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after acquiring an additional 96,084 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

CSTL has been the topic of several research reports. Robert W. Baird decreased their price target on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings lowered shares of Castle Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Morgan Stanley raised shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Wall Street Zen lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.33.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.